Express News | Sanofi's vaccine sales started ahead of schedule, exceeding market expectations.
Why Sanofi Stock Flew Higher on Friday
Health Care Down After Mixed Earnings -- Health Care Roundup
Eli Lilly's Newly FDA-Approved Eczema Drug Improves Skin And Itch In Patients Previously Treated With Sanofi/Regeneron's Dupixent
Sanofi (SNY) Q3 2024 Earnings Call Transcript Summary
Sanofi (SNY) Q3 2024 Earnings Call Transcript
Sanofi Reports Strong Q3 Growth and Raises EPS Guidance
6-K: Report of foreign private issuer (related to financial reporting)
Sanofi Shocks the Market: Massive Q3 Surge, Game-Changing Moves, and Bold Divestment Plans
Sanofi-backed Agomab Raises $89m to Advance Fibrotic Disease Treatments
European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading
Lilly's Ebglyss Shown to Be Effective in Former Dupixent Users
4 Stocks to Watch on Friday: CNC, DECK and More
Sector Update: Health Care Stocks Advance Pre-Bell Friday
Exchange-Traded Funds, Equity Futures Higher Pre-Bell Friday as Investor Risk Appetite Recovers Amid Earnings
Express News | Sanofi's sales in the China market in the third quarter were 0.757 billion euros.
Sanofi Shares Are Trading Higher After the Company Reported a Year-over-year Increase in Q3 Adjusted EPS Results and Better-than-expected Q3 Sales Results.
Sanofi Posts Q3 Revenue Beat as Dupixent Sales Jump
Sanofi Earns $5B Q3 Core Profit On Strong Dupixent And Vaccine Sales, Raises 2024 Forecast
Sanofi Sees Third-quarter Growth Boosted by Earlier-than-anticipated Vaccine Sales